Key Market Indicators
Sales of Korean antihypertensive medicines are set to reach nearly $37 million by 2026, according to recent projections. This represents a 1.1 percent annual growth since 2021, when sales were at $35 million. Since 2013, demand for antihypertensive medicines in Korea has been increasing at 6.4 percent every year. In 2021, the country ranked 12th in global sales, though the Czech Republic overtook it with $35 million in sales. Italy, Spain and Australia came in second, third and fourth respectively.
